You are here

  • Home
  • Archive
  • Volume 7, Issue Suppl 1
  • O-9 Phase 3 study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation (OIC) in cancer patients

Article info

Article menu

Download PDFPDF

Oral Presentations
O-9 Phase 3 study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation (OIC) in cancer patients
Free

Authors

Citation

Yokota T, Katakami N, Harada T, et al
O-9 Phase 3 study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation (OIC) in cancer patients
BMJ Supportive & Palliative Care 2017;7:A3-A4.

Publication history

  • First published March 1, 2017.
Online issue publication 
March 29, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions